NCT07002281已完成1 期
A Single-center, Open-label, Single-dose Clinical Trial to Evaluate the Absorption, Metabolism, and Excretion of 3 mg/100 μCi [14C]Azvudine Suspension in Vivo in Healthy Male Subjects
Henan Genuine Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2024年7月22日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of total radioactive material in whole blood and plasma
研究概览
简要总结
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase (RdRp).
This trial uses a single-center, open-label, single-dose adaptive design aimed at investigating the pharmacokinetic characteristics of total radioactivity of [14C]-labeled Azvudine in whole blood and plasma of healthy male subjects, to quantitatively analyze the total radioactivity in exhaled gas and excreta of healthy male subjects after oral administration of [14C]Azvudine suspension, to obtain data on the mass balance in the human body, and to determine the main excretion routes. Biological sample collection and safety examination will be performed in this trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male subjects aged 18~45 years old;
- •Body mass index (BMI) within the range of 18.0-30.0 (including the critical value) (BMI = weight (kg) / height 2 (m2)), the weight should be ≥ 50.0kg;
- •Subjects who are judged by the investigator to be in good health, with normal results of physical examination, vital signs, electrocardiogram, and laboratory examinations or abnormal but without clinical significance;
- •Subjects who have no fertility plan during the study period and within 1 year after the end of the trial and agree to take effective non-drug contraceptive measures during the trial (except for those who have taken permanent contraceptive measures, such as vasectomy, etc.), and have no sperm donation plan;
- •Subjects who are willing to follow the visits, study treatments, laboratory tests, and other study-related procedures and requirements specified in the study protocol, understand and sign the informed consent form.
排除标准
- •Those who are allergies, with a history of drug or food allergies, especially those who are allergic to any of the ingredients in this product and excipients;
- •Those who are positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or treponema pallidum antibody;
- •Those who cannot tolerate venipuncture blood collection and/or have a history of blood sickness and needle sickness;
- •Those who have a history of mental illness, family history of mental illness, or chronic or serious diseases of the central nervous system, cardiovascular, liver, kidney, lung, metabolic, blood, bone and other systems;
- •Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal (ULN);
- •Glomerular filtration rate< 90 mL/min/1.73m2;
- •Patients with long QT syndrome or its family history, or QTcF interval (Fridericia's correction) > 450 ms; Intraventricular block or left and right bundle branch block and/or QRS>120 ms; Frequent ventricular ectopic beats (1 premature ventricular contraction occurred on any 10-second ECG during the screening period≥); or abnormal resting heart rate (>100 bpm);
- •Previous or current swallowing dysfunction, active gastrointestinal diseases (such as chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease) or other diseases that significantly affect drug absorption, distribution, metabolism and excretion;
- •Hemorrhoids or perianal disease accompanied by regular/hematochezia;
- •Those who have donated blood within 3 months before screening, or have lost ≥ 200 ml of blood, or plan to donate blood during the study period;
- •Those who have been vaccinated with the new crown vaccine within 2 weeks before screening or other vaccines within 3 months before screening or plan to be vaccinated during the trial;
- •Intake of > 6 servings of coffee, tea, cola, energy drinks, or other caffeinated products per day within 3 months prior to screening (one serving ≈ 120 mg of caffeine); or ingestion of foods or drinks containing high levels of caffeine, xanthines, alcohol, flavonoids (such as: grapefruit (juice), grapefruit (juice), orange (juice), etc.) within 24 hours before administration;
- •Use of any drug that inhibits or induces hepatic drug metabolism enzymes within 1 month before administration (such as: inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; Inhibitors - SSRIs antidepressants, cimetidine, diltiazem macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines, etc.);
- •Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, and health care products within 14 days before administration;
- •Those who have participated in other clinical trials within 3 months before screening;
- •Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study;
- •Those who have a history of alcoholism within 12 months before screening (drinking ≥ 14 units of alcohol per week: 1 unit = 360 mL of beer, or 45 mL of spirits, or 150 mL of wine) or those who have a positive alcohol breath test before enrollment;
- •Known or suspected history of drug abuse (e.g., morphine, methamphetamine, ketamine, methylenedioxyamphetamine, tetrahydrocannabinolic acid, cocaine, etc.), or positive test for addictive substances;
- •Surgical surgery within 3 months prior to screening, or planned surgical surgery during the current study period;
- •Participated in radiolabeled clinical trials within 1 year before screening;
- •Workers who require long-term exposure to radioactive conditions, or who have had significant radioactive exposure within 1 year before the test (≥ 2 chest/abdominal CT examinations, or ≥ 3 other types of X-ray examinations);
- •The investigator judges that there are other circumstances that make subjects unsuitable to participate in this study.
研究组 & 干预措施
Healthy male subjects
Experimental
干预措施: [14C]Azvudine suspension (Drug)
结局指标
主要结局
Pharmacokinetics (PK): Maximum Concentration (Cmax) of total radioactive material in whole blood and plasma
时间窗: Up to 96 hours post-dose
Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of total radioactive material in whole blood and plasma
时间窗: Up to 96 hours post-dose
Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of total radioactive material in whole blood and plasma
时间窗: Up to 96 hours post-dose
Pharmacokinetics (PK): Elimination half-life (t1/2) of total radioactive material in whole blood and plasma
时间窗: Up to 96 hours post-dose
The total radioactivity allocation ratio
时间窗: Up to 96 hours post-dose
The total radioactivity and the percentage to the total administered dose
时间窗: Up to 168 hours post-dose
次要结局
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of Azvudine and its metabolites in plasma(Up to 96 hours post-dose)
- Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Azvudine and its metabolites in plasma(Up to 96 hours post-dose)
- Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of Azvudine and its metabolites in plasma(Up to 96 hours post-dose)
- Pharmacokinetics (PK): Elimination half-life (t1/2) of Azvudine and its metabolites in plasma(Up to 96 hours post-dose)
- Percentage of Azvudine metabolites in plasma to total exposed AUC(Up to 96 hours post-dose)
- Occurrence of Adverse Events(From enrollment to the end of the study on Day 22.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly SubjectsNCT06991634Henan Genuine Biotech Co., Ltd.24
已完成
1 期
A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)NCT07002229Henan Genuine Biotech Co., Ltd.15
Unknown
3 期
Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive PatientsHIV-infection/AidsNCT04303598HeNan Sincere Biotech Co., Ltd720
已完成
1 期
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenHIV InfectionsNCT01504841National Institute of Allergy and Infectious Diseases (NIAID)26
招募中
2 期
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTAllogeneic Hematopoietic Stem Cell TransplantationAcute Lymphoblastic LeukemiaNCT05809167The First Affiliated Hospital of Soochow University55